Grail's Galleri MCED Test Expected to Drive Growth Amid FDA Submission and Guidance Update
ByAinvest
Friday, Jan 23, 2026 9:13 pm ET1min read
GRAL--
Grail's shares rose 13% as investors anticipate FDA approval for its multi-cancer early detection test in Q1 2026, which would significantly boost commercial sales. The company's 2025 revenue guidance was raised to $147-148 million, with Galleri expected to generate $136-137 million. Grail's cash burn has decreased to $274 million in 2025 from $579 million in 2024, and the company has a cash position of $904 million, providing a "runway into 2030".
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet